Safety of 8-aminoquinolines given to people with G6PD deficiency: Protocol for systematic review of prospective studies

BMJ Open

Volumn 4, Issue 5, 2014, Pages

  Uthman, Olalekan A ^a,b   Saunders, Rachel ^b   Sinclair, David ^b   Graves, Patricia ^c   Gelband, Hellen ^d   Clarke, Aileen ^a   Garner, Paul ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c JAMES COOK UNIVERSITY   (Australia)

^d Center for Disease Dynamics Economics and Policy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; ARTEMISININ; HEMOGLOBIN; PRIMAQUINE; 8-AMINOQUINOLINE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT;

ACUTE KIDNEY FAILURE; COCHRANE LIBRARY; COHORT ANALYSIS; DATA BASE; DRUG SAFETY; EMBASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HETEROZYGOTE; HUMAN; INFORMED CONSENT; MALARIA FALCIPARUM; MEDLINE; PHENOTYPIC VARIATION; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PUBLIC HEALTH; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT DURATION; WORLD HEALTH ORGANIZATION; COMPLICATION; LITERATURE; MALARIA; METHODOLOGY;

AMINOQUINOLINES; ANTIMALARIALS; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; MALARIA; PRIMAQUINE; PROSPECTIVE STUDIES; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC;

EID: 84901488642     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004664     Document Type: Review

References (45)

1. WHO. Guidelines for the treatment of malaria. 2nd edn. Geneva, Switzerland: World Health Organization, 2010.
2. Betuela I, Bassat Q, Kiniboro B, et al. Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age. Antimicrob Agents Chemother 2012;56:2146-9.
3. Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem 2009;44:937-53.
4. Bunnag D, Karbwang J, Thanavibul A, et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 1994;88:218-19. (Pubitemid 24139695)
5. Baird JK, Lacy MD, Basri H, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 2001;33:1990-7. (Pubitemid 33152392)
6. WHO. WHO Evidence Review Group: the safety and effectiveness os single dose primaquine as a P. falciparium gametoctyocide. Meeting Report. Geneva, Switzerland: World Health Organization, 2012.
7. Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 2003;19:115-20. (Pubitemid 36338074)
8. Clayman CB, Arnold J, Hockwald RS, et al. Toxicity of primaquine in Caucasians. J Am Med Assoc 1952;149:1563-8.
9. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008;371:64-74.
10. Howes RE, Piel FB, Patil AP, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 2012;9:e1001339.
11. Howes RE, Battle KE, Satyagraha AW, et al. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol 2013;81:133-201.
12. Luzzatto L. Genetics of red cells and susceptibility to malaria. Blood 1979;54:961-76. (Pubitemid 10197539)
13. Luzzatto L, Bienzle U. The malaria/G.-6-P.D. hypothesis. Lancet 1979;1:1183-4.
14. Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med (Berl) 1998;76:581-8. (Pubitemid 28332727)
15. Beutler E. G6PD deficiency. Blood 1994;84:3613-36. (Pubitemid 24362456)
16. Guindo A, Fairhurst RM, Doumbo OK, et al. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med 2007;4:e66.
17. Peters AL, Van Noorden CJ. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. J Histochem Cytochem 2009;57:1003-11.
18. Hedrick PW. Population genetics of malaria resistance in humans. Heredity (Edinb) 2011;107:283-304.
19. Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 1961;190:372-3.
20. Edwards CQ. Anemia and the liver. Hepatobiliary manifestations of anemia. Clin Liver Dis 2002;6:891-907, viii.
21. Burgoine KL, Bancone G, Nosten F. The reality of using primaquine. Malar J 2010;9:376.
22. Fiorelli G, Martinez di Montemuros F, Cappellini MD. Chronic non-spherocytic haemolytic disorders associated with glucose-6-phosphate dehydrogenase variants. Baillieres Best Pract Res Clin Haematol 2000;13:39-55. (Pubitemid 32834310)
23. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011;24:377-410.
24. Graves PM, Gelband H, Garner P. Primaquine for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev 2012;9:CD008152.
25. Barber MA, Justus BR, James YB. Malaria studies on the firestone rubber plantation in Liberia, West Africa. Am J Hyg 1932;15:601-33.
26. Clyde DF. Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline in Tanganyika. Bull World Health Organ 1962;27:203-12.
27. Maude RJ, Socheat D, Nguon C, et al. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. PloS ONE 2012;7:e37166.
28. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis 2013;13:175-81.
29. WHO. World Malaria Report, 2011. Annex 3b. Country Antimalarial Drug Policies: By Region, 2010. Geneva, Switzerland: World Health Organization, 2011.
30. White NJ, Qiao LG, Qi G, et al. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J 2012;11:418.
31. Recht J, Ashley E, White N. 8-aminoquinolines Safety Review for WHO Primaquine ERG. Unpublished 2012.
32. Bruce-Chwatt LJ. Malaria research and eradication in the USSR. A review of Soviet achievements in the field of malariology. Bull World Health Organ 1959;21:737-72.
33. WHO. Single dose Primaquine as a gametocytocide in Plasmodium falciparum malaria. Updated WHO Policy Recommendation (October 2012). Geneva, Switzerland: Global Malaria Programme. World Health Organization, 2012. http://www.who.int/ malaria/pq-updated-policy-recommendation-en-102012.pdf
34. Eziefula AC, Gosling R, Hwang J, et al. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J 2012;11:360.
35. Recht J, Ashley E, White N. Safety of 8-aminoquinolines: a review. Mahidol Oxford Research Unit, 2012.
36. Uthman OA, Graves P, Gelban H, et al. Safety of 8-aminoquinolones given to people with G6PD deficiency: systematic review of prospective studies. PROSPERO 2013;CRD42013006518. http://www.crd.york.ac.uk/PROSPERO/display-record. asp? ID=CRD42013006518
37. Cochrane Effective Practice and Organisation of Care Group. Suggested risk of bias criteria for EPOC reviews. Secondary Suggested risk of bias criteria for EPOC reviews 2014. http://epoc.cochrane.org/sites/epoc.cochrane. org/files/uploads/ Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.pdf (accessed 14 Mar 2014).
38. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ (Clinical Research ed) 2004;328:1490.
39. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bull World Health Organ 1989;67:601-11.
40. Hockwald RS, Arnold J, Clayman CB, et al. Toxicity of primaquine in Negroes. J Am Med Assoc 1952;149:1568-70.
41. Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ 1981;59:391-5. (Pubitemid 11024762)
42. Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006;75:402-15. (Pubitemid 46941297)
43. Louicharoen C, Patin E, Paul R, et al. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science 2009;326:1546-9.
44. Buchachart K, Krudsood S, Singhasivanon P, et al. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian J Trop Med Public Health 2001;32:720-6. (Pubitemid 33642187)
45. Beutler E, Duparc S. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 2007;77:779-89. (Pubitemid 351844308)